Evidence map›Paper›PMID 33765333›Full record

ArticleMolecular carcinogenesis2021

Enrichment of progenitor cells by 2-acetylaminofluorene accelerates liver carcinogenesis induced by diethylnitrosamine in vivo.

María Paulette Castro-Gil, Ricardo Sánchez-Rodríguez, Julia Esperanza Torres-Mena, Carlos David López-Torres, Valeria Quintanar-Jurado, Nayeli Belem Gabiño-López, Saúl Villa-Treviño, Luis Del-Pozo-Jauner, Jaime Arellanes-Robledo, Julio Isael Pérez-Carreón

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Effects of the Polar Fraction ofInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

María Paulette Castro-GilLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.ORCID 0000-0001-8670-1219
Ricardo Sánchez-RodríguezFoundation Istituto di Ricerca Pediatrica-Città della Speranza, Padova, Italy.ORCID 0000-0002-9111-2176
Julia Esperanza Torres-MenaLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.ORCID 0000-0003-0514-5244
Carlos David López-TorresLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.ORCID 0000-0002-8426-6193
Valeria Quintanar-JuradoLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.
Nayeli Belem Gabiño-LópezLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.ORCID 0000-0002-3654-4961
Saúl Villa-TreviñoDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute, Ciudad de México, Mexico.ORCID 0000-0002-8292-8157
Luis Del-Pozo-JaunerDepartment of Pathology, University of South Alabama, Alabama, USA.ORCID 0000-0002-2551-0301
Jaime Arellanes-RobledoLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.ORCID 0000-0001-7363-4870
Julio Isael Pérez-CarreónLaboratory of Liver Diseases, National Institute of Genomic Medicine, Ciudad de México, Mexico.ORCID 0000-0001-9284-7775
National Institute of Genomic Medicine · MXCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXUniversity of Alabama · USUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential role of hepatocytes versus hepatic progenitor cells (HPC) on the onset and pathogenesis of hepatocellular carcinoma (HCC) has not been fully clarified. Because the administration of 2-acetylaminofluorene (2AAF) followed by a partial hepatectomy, selectively induces the HPC proliferation, we investigated the effects of chronic 2AAF administration on the HCC development caused by the chronic administration of the carcinogen diethylnitrosamine (DEN) for 16 weeks in the rat. DEN + 2AAF protocol impeded weight gain of animals but promoted prominent hepatomegaly and exacerbated liver alterations compared to DEN protocol alone. The tumor areas detected by γ-glutamyl transferase, prostaglandin reductase-1, and glutathione S-transferase Pi-1 liver cancer markers increased up to 80% as early as 12 weeks of treatment, meaning 6 weeks earlier than DEN alone. This protocol also increased the number of Ki67-positive cells and those of CD90 and CK19, two well-known progenitor cell markers. Interestingly, microarray analysis revealed that DEN + 2AAF protocol differentially modified the global gene expression signature and induced the differential expression of 30 genes identified as HPC markers as early as 6 weeks of treatment. In conclusion, 2AAF induces the early appearance of HPC markers and as a result, accelerates the hepatocarcinogenesis induced by DEN in the rat. Thus, since 2AAF simultaneously administrated with DEN enriches HPC during hepatocarcinogenesis, we propose that DEN + 2AAF protocol might be a useful tool to investigate the cellular origin of HCC with progenitor features.

Indexed as

2-AcetylaminofluoreneAnimalsCarcinogensCarcinoma, HepatocellularCell ProliferationDiethylnitrosamineGene Expression Regulation, NeoplasticHepatomegalyLiver NeoplasmsMaleRatsRats, Inbred F344Stem CellsTransforming Growth Factor beta12-AcetylaminofluoreneCarcinogensDiethylnitrosamineTgfb1 protein, ratTransforming Growth Factor beta1cancer biomarkerscellular origin of liver cancercirrhosishepatocellular carcinomaliver progenitor cellsoval cells

Identifiers

PMID33765333
PMCPMC8251613
OpenAlexW3137145003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.